Pharmaceuticals - Community Register


Community list of not active veterinary medicinal products


Product information

Invented name: Yarvitan
Auth. number : EU/2/06/063
Active substance : Mitratapide
ATC: Anatomical main group: QA - Alimentary tract and metabolism
Therapeutic subgroup: QA08 - Antiobesity preparations, excl. diet products
Pharmacological subgroup: QA08A - Antiobesity preparations, excl. diet products
Chemical subgroup: QA08AB - Peripherally acting antiobesity products
Chemical substance: QA08AB90 - mitratapide
(See WHO ATCvet Index)
Indication: As an aid in the management of overweight and obesity in adult dogs
Marketing Authorisation Holder: Janssen Pharmaceutica N.V.
Turnhoutseweg 30, 2340 Beerse, België
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
16/11/2006 Centralised - Authorisation EMEA/V/C/113 (2006)5549 of 14/11/2006
16/04/2007 Centralised - Variation EMEA/V/C/113/IB/1
Updated with Decision(2007)4075 of 27/08/2007
29/08/2007 Centralised - Transfer Marketing Authorisation Holder EMEA/V/C/113/T/2 (2007)4075 of 27/08/2007
20/10/2008 Centralised - Variation (no change in Commission Decision) EMEA/V/C/113/II/3
12/08/2011 Centralised - Withdrawal (2011)5945 of 10/08/2011